Welcome to our dedicated page for DOMINARI HOLDINGS SEC filings (Ticker: DOMH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning a single Dominari Holdings Inc. filing can feel like reading two companies at once—oncology drug-development updates on one page, broker-dealer capital ratios on the next. When a 300-page 10-K combines lab data, underwriting income and high-performance computing investments, even seasoned analysts spend hours hunting for answers.
Stock Titan solves that problem. Our AI highlights exactly where the pancreatic-cancer trial costs sit, flags income swings inside Dominari Securities, and decodes every regulatory footnote in plain language. Need Dominari Holdings insider trading Form 4 transactions or a Dominari Holdings quarterly earnings report 10-Q filing? They appear here in real time, side-by-side with easy-to-read summaries.
- Dominari Holdings Form 4 insider transactions real-time alerts track executive buys and sells the moment they hit EDGAR.
- Dominari Holdings SEC filings explained simply—AI tags clinical milestones, brokerage metrics and tech-investment disclosures.
- Dominari Holdings earnings report filing analysis compares R&D spend to underwriting revenue so you can spot cash-flow pivots fast.
Whether you’re understanding Dominari Holdings SEC documents with AI or reviewing a Dominari Holdings annual report 10-K simplified, every filing type is covered: the Dominari Holdings proxy statement executive compensation that outlines equity grants, Form 4 data on Dominari Holdings executive stock transactions Form 4, or an Dominari Holdings 8-K material events explained alert when trial results break. Real-time updates, concise AI summaries and historical archives mean informed decisions come quicker—no matter how many sectors Dominari spans.
Dominari Holdings (Nasdaq:DOMH) filed an 8-K reporting two material governance and compensation actions dated June 24–27, 2025.
Executive compensation: Amendments to CEO Anthony Hayes and President Kyle Wool employment agreements eliminate future stock grants tied to net-revenue milestones in favor of an additional cash bonus. All other terms remain unchanged.
Board change: Director Soo Yu resigned effective June 27, 2025 for non-dispute reasons and continues as Special Projects Manager. The Board size shrinks from seven to six.
- No financial statements were included.
- Amendments are filed as Exhibits 10.1 & 10.2.
Investors should weigh lower dilution against higher cash outflows and any governance impact from the board reduction.
FAQ
What is the current stock price of DOMINARI HOLDINGS (DOMH)?
What is the market cap of DOMINARI HOLDINGS (DOMH)?
What are the core business segments of Dominari Holdings Inc?
Which therapeutic areas does the biotech division target?
How does Dominari Securities LLC contribute to the company?
What role do emerging technologies play in Dominari Holdings Inc's strategy?
How is Dominari Holdings Inc positioned in its competitive landscape?
What distinguishes the company’s approach to innovation?
How does the company manage its diversified portfolio?
What benefits do stakeholders gain from Dominari Holdings Inc's diversified operations?
